Home » Topics » Regulatory » EMA

EMA
RSS

EMA accepts Optimer Pharma's fidaxomicin MAA for review

Aug. 20, 2010

European Commission grants midostaurin orphan drug status in mastocytosis

Aug. 18, 2010

European Commission grants orphan designation to Vertex's cystic fibrosis candidate

Aug. 18, 2010

EMA validates CTI's expanded pediatric program for pixantrone in NHL

Aug. 16, 2010

Dexamethasone intravitreal implant receives E.U. orphan drug status for noninfectious uveitis

Aug. 16, 2010

MK-4827 receives E.U. orphan drug status in ovarian cancer

Aug. 16, 2010

European Commission grants orphan status to bosutinib in CML

Aug. 13, 2010

Tranilast obtains orphan drug status for prevention of scarring in glaucoma surgery

Aug. 10, 2010

HBGF-1-coated biodegradable device receives E.U. orphan drug status for spinal cord injury

Aug. 10, 2010

EMA grants octenidine orphan drug status for sepsis in premature infants

Aug. 10, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Orexin OX2 receptor agonists disclosed in Vertex Pharmaceuticals patent
BioWorld Science
Vertex Pharmaceuticals Inc. has patented new macrocyclic sulfonamide orexin OX2 receptor agonists potentially useful for the treatment of amyotrophic lateral...